… of biologic therapy, and particularly the use of anti-tumor necrosis factor alpha (TNF-a)
therapy, has significantly changed the treatment and management of Crohn’s disease (CD). The …

… Here, we discuss the most important findings on the possible use of immunomodulators or
biologics in the prevention and treatment of intestinal strictures in Crohn’s disease patients. …

… guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) on the
use of biologics for the management of Crohn's disease (CD) [2]. The key for answering the …

… Crohn's disease (CD), a chronic inflammatory disease of the gastrointestinal tract of unknown
etiology, is not available, so patients require lifelong management … Bowel Disease felt the …

… of biologic therapy in the treatment of moderate-to-severe Crohn's disease, both first line
and after previous biologic … efficacy and safety of biologics in patients with Crohn's disease. …

… ), can be used as maintenance medications for Crohn disease, but are less effective than
biologic therapies or combination therapies with biologics. The SONIC trial 25 evaluated the …

… Crohn's disease (CLASSIC-I) study was carried out in 299 participants. In this Phase III
dose-ranging trial, 160 mg subcutaneous injection of adalimumab at week 0, followed by 80 mg …

… The SONIC trial revealed the beneficial effect of the combination therapy (infliximab and
azathioprine (AZA)) in patients with moderate to severe Crohn's disease and naive to biologics. …

Background and Aims We evaluated the cost-effectiveness of early [≤2 years after diagnosis]
compared with late or no biologic initiation [starting biologics >2 years after diagnosis or …

… Ustekinumab has been recently approved for its use in patients with Crohn’s disease. Its …
with Crohn’s disease refractory to anti-tumor necrosis factor therapy. This biologic agent …